Several other research analysts have also recently weighed in on the company. Guggenheim assumed coverage on Healthequity in a research report on Tuesday, April 14th. They issued a buy rating and a $56.00 price objective on the stock. SVB Leerink started coverage on shares of Healthequity in a research report on Monday, April 13th. They set a market perform rating and a $53.00 price target for the company. Raymond James lowered their price objective on shares of Healthequity from $90.00 to $75.00 and set a strong-buy rating on the stock in a research report on Wednesday, April 8th. Barrington Research reissued a buy rating and set a $65.00 target price on shares of Healthequity in a research report on Monday, June 1st. Finally, Cantor Fitzgerald lowered their price target on shares of Healthequity from $80.00 to $70.00 and set an overweight rating on the stock in a report on Wednesday, June 3rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $65.57.
Shares of HQY stock opened at $51.56 on Thursday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.11 and a quick ratio of 2.11. The firm has a 50-day moving average of $58.13 and a 200-day moving average of $59.89. Healthequity has a one year low of $34.40 and a one year high of $88.78. The company has a market cap of $3.68 billion, a P/E ratio of 1,718.67, a P/E/G ratio of 3.72 and a beta of 1.52.
In other news, CEO Jon Kessler sold 100,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $62.59, for a total transaction of $6,259,000.00. Following the sale, the chief executive officer now directly owns 405,715 shares in the company, valued at $25,393,701.85. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 3.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of HQY. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Healthequity in the first quarter worth $25,000. Weaver Consulting Group bought a new stake in Healthequity during the second quarter valued at $29,000. Banque Cantonale Vaudoise purchased a new position in Healthequity during the first quarter worth about $25,000. First Horizon Advisors Inc. increased its stake in Healthequity by 57.5% in the 1st quarter. First Horizon Advisors Inc. now owns 849 shares of the company’s stock worth $42,000 after acquiring an additional 310 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Healthequity by 27.8% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 887 shares of the company’s stock valued at $45,000 after acquiring an additional 193 shares in the last quarter. Institutional investors and hedge funds own 97.31% of the company’s stock.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Article: The primary rules of Elliott Wave theory
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.